Skip to content
2000
image of Certolizumab-Induced Urticarial Vasculitis: A Case Report

Abstract

Introduction

Certolizumab (CZ) is a tumour necrosis factor-α (TNF-α) blocking agent with excellent efficiency in rheumatoid arthritis (RA). Urticarial vasculitis (UV) induced by CZ is a rare side effect. Herein, we describe a patient with UV probably induced by CZ therapy.

Case Presentation

A 33-year-old female with RA was treated with methotrexate and corticosteroids, which resulted in no improvement. The patient was switched to CZP, and one week later, she developped urticaria (erythematous and edematous plaques). The diagnosis of urticarial vasculitis related to CZ was suspected. The results of microbiological and autoimmunity tests ruled out other causes of vasculitis. The diagnosis of CZ-induced-UV was retained (Naranjo’s score: 5). CZ was withdrawn, which led to rapid resolution of skin lesions.

Conclusion

With the increasing use of CZ, physicians should be aware of the possibility of UV associated with CZ.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cds/10.2174/0115748863356947250302165303
2025-03-13
2025-07-23

  • From This Site

    /content/journals/cds/10.2174/0115748863356947250302165303
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. da Silva Cendon Duran C. da Paz A.S. Santiagu MB Vasculitis induced by biological agents used in rheumatology practice: A systematic review. Arch. Rheumatol. 2022 37 2 300 310 10.46497/ArchRheumatol.2022.9049 36017201
    [Google Scholar]
  2. Naranjo C.A. Busto U. Sellers E.M. Sandor P. Ruiz I. Roberts E.A. Janecek E. Domecq C. Greenblatt D.J. A method for estimating the probability of adverse drug reactions. Clin. Pharmacol. Ther. 1981 30 2 239 245 10.1038/clpt.1981.154 7249508
    [Google Scholar]
  3. Young J.N. Rivera-Oyola R. Poplausky D. Suemitsu Y. Kim R.H. Doroshow D. Gulati N. A case of urticarial vasculitis associated with atezolizumab. JAAD Case Rep. 2024 43 30 33 10.1016/j.jdcr.2023.09.042 38162407
    [Google Scholar]
  4. Mehregan D.R. Gibson L.E. Pathophysiology of urticarial vasculitis. Arch. Dermatol. 1998 134 1 88 89 10.1001/archderm.134.1.88 9449915
    [Google Scholar]
  5. Ouni B. Fathallah N. Ben-Sayed N. Slim R. Abdessayed N. Anoun J. Ben Salem C. Enalapril-lercanidipine combination induced leukocytoclastic vasculitis: A case report. Br. J. Clin. Pharmacol. 2021 87 1 210 211 10.1111/bcp.14346 32410251
    [Google Scholar]
  6. Grau R.G. Drug-induced vasculitis: New insights and a changing lineup of suspects. Curr. Rheumatol. Rep. 2015 17 12 71 10.1007/s11926‑015‑0545‑9 26503355
    [Google Scholar]
  7. Gutiérrez-González L.A. Biological therapy-induced systemic vasculitis. Curr. Rheumatol. Rep. 2016 18 7 39 10.1007/s11926‑016‑0588‑6 27165496
    [Google Scholar]
  8. Ouni B. Mansour K. Sassi M. Sriha B. Bensayed N. Fathallah N. Slim R. Silodosin-induced leukocytoclastic vasculitis: A first case report. Eur. J. Dermatol. 2024 34 1 92 93 10.1684/ejd.2024.4613 38557466
    [Google Scholar]
  9. Woodruff C.M. Botto N. The role of patch testing in evaluating delayed hypersensitivity reactions to medications. Clin. Rev. Allergy Immunol. 2022 62 3 548 561 10.1007/s12016‑022‑08924‑2 35113364
    [Google Scholar]
  10. Woody M. Warren D. Speck L. Jackson J. Leukocytoclastic vasculitis drug reaction to certolizumab pegol. Proc. Bayl. Univ. Med. Cent. 2017 30 2 213 214 10.1080/08998280.2017.11929591 28405087
    [Google Scholar]
  11. Horai Y. Ishikawa H. Iwanaga N. Izumi Y. Matsuoka Y. Miura S. Kawakami A. Development of hypocomplementemic urticarial vasculitis during certolizumab pegol treatment for rheumatoid arthritis: A case report. J. Clin. Pharm. Ther. 2020 45 5 1179 1182 10.1111/jcpt.13117 31990069
    [Google Scholar]
  12. Bostan E. Gulseren D. Yalici-Armagan B. Dogan S. Ates-Ozdemir D. Gokoz O. Kalyoncu U. Atakan N. Vasculitis during certolizumab pegol and secukinumab treatment: Report of two cases. Dermatol. Ther. 2021 34 4 e15007 10.1111/dth.15007 34046982
    [Google Scholar]
/content/journals/cds/10.2174/0115748863356947250302165303
Loading
Certolizumab-Induced Urticarial Vasculitis: A Case Report
Bentham Science Publishers ; https://doi.org/10.2174/0115748863356947250302165303
/content/journals/cds/10.2174/0115748863356947250302165303
/content/journals/cds/10.2174/0115748863356947250302165303
Loading

Data & Media loading...


  • Article Type:     Case Report
Keywords: pharmacovigilance ; adverse drug reaction ; Certolizumab ; vasculitis ; inflammatory diseases ; rheumatoid arthritis ; case report ; tumour necrosis factor-α

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test